A few weeks ago, Grant Ogren and Rhea Ashby-Durall, the executive director and the outreach manager of SAN (formerly Spokane AIDS Network), met with their representative from Gilead Sciences, the ...
ViiV Healthcare’s combination injectable human immunodeficiency virus (HIV) medication was preferred over a daily tablet in treatment-naïve patients in a Phase IIIb trial. A global specialist in HIV ...
The Food and Drug Administration has given the green light to ViiV Healthcare for its new once-monthly HIV treatment. The company's Cabenuva (cabotegravir and rilpivirine, injectable formulation) was ...
GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment
GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...
Multiple real-world studies show consistent high effectiveness of Vocabria + Rekambys (cabotegravir + rilpivirine LA (CAB+RPV LA)) across a broad range of populations Implementation science data for ...
Hosted on MSN
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending ...
Although a cure is likely still a ways off, continuing to pursue long-acting injectable treatments and PrEP is key to reducing cases of HIV. I think what we're seeing is innovation in terms of ...
Implementation science data for Apretude (cabotegravir long-acting (CAB LA) for PrEP) demonstrate 95% of participants were happy they switched from oral PrEP to CAB LA Jean van Wyk, MBChB, MFPM, Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results